First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties-Reference-Cited by-同舟云学术

First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties

Published:2022-06-28 Issue:9 Volume:61 Page:1271-1284
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Kazama Junichiro James,Koiwa Fumihiko,Yokoyama Keitaro,Fukagawa Masafumi,Asano Kenji,Honda Daisuke^ORCID,Akizawa Tadao

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-022-01139-w.pdf

Reference25 articles.

1. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6(4):913–21. https://doi.org/10.2215/CJN.06040710.

2. Fraser WD. Hyperparathyroidism. Lancet. 2009;374(9684):145–58. https://doi.org/10.1016/S0140-6736(09)60507-9.

3. Goodman WG, Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int. 2001;59(3):1187–201. https://doi.org/10.1046/j.1523-1755.2001.0590031187.x.

4. Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, CKD-MBD Guideline Working Group; Japanese Society for Dialysis Therapy, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013;17(3):247–88. https://doi.org/10.1111/1744-9987.12058.

5. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol. 2003;14(3):575–83. https://doi.org/10.1097/01.asn.0000050224.03126.ad.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of calcimimetics on fractures in dialysis patients with secondary hyperparathyroidism: meta-analysis of randomized trials;Journal of Bone and Mineral Metabolism;2024-03-27

2. Multicentre, open-label, randomised, controlled trial to compare early intervention with calcimimetics and conventional therapy in preventing coronary artery calcification in patients with secondary hyperparathyroidism (UPCOMING): a study protocol;BMJ Open;2024-01

3. Switching from etelcalcetide to upacicalcet in maintenance hemodialysis patients;Nihon Toseki Igakkai Zasshi;2024

4. Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism;Clinical Journal of the American Society of Nephrology;2023-09-11

5. Phase 2 study of upacicalcet in Japanese haemodialysis patients with secondary hyperparathyroidism: an intraindividual dose-adjustment study;Clinical Kidney Journal;2023-09-04